Share on LinkedInShare on LinkedIn

ARTICLE · 13 OCTOBER 2017

General Data Protection Regulation: The Impact On Clinical Trials And Data Subjects

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

Richard Dickinson, Jackie Mulryne and Zoe Walkinshaw, Arnold & Porter Kaye Scholer LLP, consider how the GDPR will impact clinical trials.

European UnionPrivacy

Richard Dickinson, Jackie Mulryne and Zoe Walkinshaw, Arnold & Porter Kaye Scholer LLP, consider how the GDPR will impact clinical trials

The EU rules on data protection seek to protect individuals by placing restrictions on the processing (collecting, storing or using) of their personal data. Under the new General Data Protection Regulation 2016/679/EU ("GDPR"), which will apply throughout the EU from May 25, 2018, these rules have been strengthened: data subjects have new rights to help ensure their data are processed securely and with adequate protections, and clearer responsibilities and obligations are placed on companies using such data.

However, these strengthened rights do not necessarily fit neatly with other sector specific legislation where large quantities of data are collected and processed. In particular, the GDPR raises some important questions for clinical trials, one of the fundamental aspects of which is the collection and analysis of sensitive

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from